This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032.

CRL has collaborated with Australian biotechnology firm Magellan Stem Cells to advance the development and clinical progress of Magellan's regenerative medicine candidate, Zelestrocel.

Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for oncology indications.

Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors.

Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.

Zealand Pharma and AI-centric biotech Generate Biomedicines have teamed up to develop protein-based therapeutics for obesity and other metabolic diseases in a deal rising to $1.2b ...

The MHRA’s new 2030 strategy plans to make drug and device regulation more efficient and patient centric by using technologies like AI.

Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies, is aiming for a $135m initial public offering (IPO) to fund clinical ...

China's NMPA has approved the MAA for Foresee Pharmaceuticals’ Camcevi 42 mg to treat adult patients with advanced prostate cancer.

Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist radiopharmaceutical developers shift from initial target validation through to clinical ...

The US FDA has approved Asahi Kasei Therapeutics’ Hovilpri 100mg tablets to treat refractory mucocutaneous HSV lesions in immunocompromised adults.

Roche now joins a growing list of big pharma and biotech players exploring the RNAi approach’s promise in treating obesity.